drugset / Trial / NCT04040699
KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor
Phase 1
Completed
48 enrolled
Peking University
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase Ib, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KN026 combined with KN046 in subjects with advanced HER2 positive solid tumors.
Timeline
- Start
- 2019-09-26
- Primary completion
- 2022-09-22
- Completion
- 2023-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ERFONRILIMAB | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | KN026 | Monoclonal antibody | 20 mg/kg | Intravenous |